Yesterday, an analyst has provided a rating update for the Healthcare company, Aurora Cannabis (ACB). GMP FirstEnergy’s analyst Martin Landry reiterates their Hold rating on the shares, with a C$7.50 price target.

According to TipRanks.com, Landry is ranked #31 out of 5135 analysts.

Read also: Aphria (APHA) Stock Soars on C$2.8 Billion Takeover Offer, But Analysts See More Value

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aurora Cannabis with a C$13.33 average price target.

Aurora Cannabis, Inc. is a Canada-based company engaged in the production and distribution of medical cannabis. The firm is vertically integrated and horizontally diversified across every key segment of the value chain; from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, home cultivation, wholesale and retail distribution. Its purpose-built facilities, which integrate technologies across all processes, are defined by automation and customization. The company also produces and sells indoor cultivation systems and hemp related food products. Aurora Cannabis was founded by Terry Booth and Steve Dobler on December 21, 2006 and is headquartered in Edmonton, Canada.

The company’s shares closed on Tuesday at C$6.68, close to its 52-week low of C$5.29.